Cite

HARVARD Citation

    Nath, K. et al. (2022). A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy. Leukemia & lymphoma. 63 (14), pp. 3488-3492. [Online]. 
  
Back to record